Cited by 84Neuroinflammation and Neurodegeneration MechanismsPain Mechanisms and TreatmentsMicroRNA in disease regulation

Dexmedetomidine Attenuates Neuroinflammation In LPS-Stimulated BV2 Microglia Cells Through Upregulation Of miR-340

Open access
Bao, Yang, Zhu, Yijun, He, Guangbao, Ni, Hongwei, Liu, Chenxia, Ma, Limin, Zhang, Lifeng, Shi, Dongping·2019·Drug Design, Development and Therapy

Abstract

BACKGROUND: Dexmedetomidine (Dex) was reported to exhibit anti-inflammatory effect in the nervous system. However, the mechanism by which Dex exhibits anti-inflammation effects on LPS-stimulated BV2 microglia cells remains unclear. Thus, this study aimed to investigate the role of Dex in LPS-stimulated BV2 cells. METHODS: The BV2 cells were stimulated by lipopolysaccharides (LPS). BV2 cells were infected with short-hairpin RNAs targeting NF-κB (NF-κB-shRNAs) and NF-κB overexpression lentivirus, respectively. In addition, miR-340 mimics or miR-340 inhibitor was transfected into BV2 cells, respectively. Meanwhile, the dual-luciferase reporter system assay was used to explore the interaction of miR-340 and NF-κB in BV2 cells. CCK-8 was used to detect the viability of BV2 cells. In addition, Western blotting was used to detect the level of NF-κB in LPS-stimulated BV2 cells. The levels of TNF-α, IL-6, IL-1β, IL-2, IL-12, IL-10 and MCP-1 in LPS-stimulated BV2 cells were measured with ELISA. RESULTS: The level of miR-340 was significantly upregulated in Dex-treated BV2 cells. Meanwhile, the level of NF-κB was significantly increased in BV2 cells following infection with lenti-NF-κB, which was markedly reversed by Dex. LPS markedly increased the expression of NF-κB and proinflammatory cytokines in BV2 cells, which were reversed in the presence of Dex. Moreover, miR-340 mimics enhanced the anti-inflammatory effects of Dex in LPS-stimulated BV2 cells via inhibiting NF-κB and proinflammatory cytokines. Furthermore, Dex obviously inhibited LPS-induced phagocytosis in BV2 cells. CONCLUSION: Taken together, our results suggested that Dex might exert anti-inflammatory effects in LPS-stimulated BV2 cells via upregulation of miR-340. Therefore, Dex might serve as a potential agent for the treatment of neuroinflammation.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2147/dddt.s210511

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Dexmedetomidine's anti-inflammatory effect is mediated by miR-340, which targets NF-κB, suppresses pro-inflammatory cytokines, induces IL-10, and decreases phagocytosis.

    “Using a BV2 cell line, it was demonstrated that its anti-inflammatory effect is mediated by miR-340, which targets NF-κB, and thus suppresses pro-inflammatory cytokines (TNF-α, IL-6, IL-1β, IL-2 and IL-12), inducing anti-inflammatory IL-10, and decreasing phagocytosis [241].”

    From MicroRNAs as Regulators of Phagocytosis (2022) · cites this paper as [241]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Bao, Y., Zhu, Y., He, G., Ni, H., Liu, C., Ma, L., Zhang, L., & Shi, D.
Affiliations
Jiading District Central Hospital (CN)
Corresponding author
Shi, Dongping
Venue
Drug Design, Development and Therapy
Published
2019-10
Volume
Volume 13
Pages
3465-3475
ISSN
1177-8881 (ISSN-L)
OpenAlex
W2978104355
Cited by
84
References
49
Citations by year
2026: 9 · 2025: 10 · 2024: 13 · 2023: 12 · 2022: 24 · 2021: 11 · 2020: 5
FWCI
4.40
Type
journal article
Language
en
Open access
Locations
  • Drug Design Development and Therapy (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
Topics
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Health Sciences › Medicine › Physiology › Pain Mechanisms and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
Keywords
dexmedetomidine, neuroinflammation, microglia, BV-2 cells, lipopolysaccharide, miR-340, NF-κB, inflammatory cytokines, anti-inflammatory activity, phagocytosis, microRNA
MeSH terms
Animals, Anti-Inflammatory Agents, Non-Steroidal, Cell Survival, Cells, Cultured, Inflammation, Lipopolysaccharides, Up-Regulation, Cytokines, NF-kappa B, Microglia, Dexmedetomidine, MicroRNAs, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review